Enhancement of anti-inflammatory tendency by SB203580, p38α specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A

Rheumatology International

Volumn 26, Issue 11, 2006, Pages 972-978

  Han, Seon Kyu ^a   Jeon, Su Jin ^a   Miyazawa, Keiji ^b   Yi, Seh Yoon ^c,d   Yoo, Young Sook ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b KISSEI PHARMACEUTICAL CO LTD   (Japan)

^c Microbia Corp   (South Korea)

^d Suwon University   (South Korea)

Author keywords

IL 1 ; IL 6; MH7A; p38 MAP kinase; Rheumatoid arthritis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKINE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; ISOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; STROMELYSIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CELL LINE; DOWN-REGULATION; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; IMIDAZOLES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PYRIDINES; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNOVIAL MEMBRANE;

EID: 33748703638     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0109-4     Document Type: Article

References (30)

1. Feldmann M, Brennan FM, Mini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
2. Feldmann M, Brennan FM, Maini RN (1996) Rheumatoid arthritis. Cell 85:307-310
3. Mukaida N, Mahe Y, Matsushima K (1990) Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 265:21128-21133
4. Dayer JM, Feige U, Edwards CK, Burger D (2001) Anti-interleukin therapy in rheumatic diseases. Curr Opin Rheumatol 13:170-176
5. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
6. Jeong JG, Kim JM, Cho HC, Hahn W, Yu SS, Kim SY (2004) Effects of IL-1β on gene expression in human rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 324:3-7
7. Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T (2000) The role p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α- or IL-1β-stimulated rheumatoid synovial fibroblasts. FEBS lett 465:23-27
8. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y (1995) Interleukin-6 (IL-6) induce the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 34:321-325
9. Tamura T et al (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90:11924-11928
10. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin 6 knock-out mice are resistant to antigen-induced arthritis. Cytokine 11:1057-1064
11. Ohshima S et al (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95:8222-8226
12. Alonzi T et al (1998) Interleukin 6 required for the development of collagen-induced arthritis. J Exp Med 187:461-468
13. Choy EHS et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 46:3143-3150
14. Bode JG et al (1999) LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 463:365-370
15. Cassatella MA et al (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutronphils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94:2880-2889
16. Miyazawa K, Mori A, Okudaira H (1998) Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. J Biochem 124:1153-1162
17. Sambrook J, Russell DW (2001) Molecular cloning. Cold Spring Harbor Laboratory Press, New York
18. Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483-1493
19. Yoshida S, Kato T, Sakurada S, Kurono C, Yang JP, Matsui N, Soji T, Okamoto T (1999) Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151-158
20. Yoshida S, Kato T, Tetsuka T, Uno K, Matsui N, Okamoto T (1999) Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol 163:351-358
21. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS, van Wijnen AJ (2003) The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 278:26589-26596
22. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H (2004) Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 23:3051-3060
23. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL (2002) Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21:7776-7785
24. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A (2001) Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108:1781-1788
25. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690
26. Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259-262
27. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D (1999) Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 42:498-506
28. Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, Fontan G (1997) Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 24:2069-2075
29. Norihiro N, Tadamitsu K (2004) Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4:386-391
30. Kamura T et al (1998) The Elogin BC complex interact with the conserved SOCS-box motif present in membrane of the SOCS, ras, WD-40 repeat and ankyrin repeat families. Genes Dev 12:3872-3881